Cargando…

Serum resistin and the risk for hepatocellular carcinoma in diabetic patients

Hepatocellular carcinoma (HCC), the predominant type of liver cancer, is a major contributor to cancer-related fatalities across the globe. Diabetes has been identified as a significant risk factor for HCC, with recent research indicating that the hormone resistin could be involved in the onset and...

Descripción completa

Detalles Bibliográficos
Autor principal: Abdalla, Mona Mohamed Ibrahim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401662/
https://www.ncbi.nlm.nih.gov/pubmed/37545641
http://dx.doi.org/10.3748/wjg.v29.i27.4271
_version_ 1785084713044541440
author Abdalla, Mona Mohamed Ibrahim
author_facet Abdalla, Mona Mohamed Ibrahim
author_sort Abdalla, Mona Mohamed Ibrahim
collection PubMed
description Hepatocellular carcinoma (HCC), the predominant type of liver cancer, is a major contributor to cancer-related fatalities across the globe. Diabetes has been identified as a significant risk factor for HCC, with recent research indicating that the hormone resistin could be involved in the onset and advancement of HCC in diabetic individuals. Resistin is a hormone that is known to be involved in inflammation and insulin resistance. Patients with HCC have been observed to exhibit increased resistin levels, which could be correlated with more severe disease stages and unfavourable prognoses. Nevertheless, the exact processes through which resistin influences the development and progression of HCC in diabetic patients remain unclear. This article aims to examine the existing literature on the possible use of resistin levels as a biomarker for HCC development and monitoring. Furthermore, it reviews the possible pathways of HCC initiation due to elevated resistin and offers new perspectives on comprehending the fundamental mechanisms of HCC in diabetic patients. Gaining a better understanding of these processes may yield valuable insights into HCC’s development and progression, as well as identify possible avenues for prevention and therapy.
format Online
Article
Text
id pubmed-10401662
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-104016622023-08-05 Serum resistin and the risk for hepatocellular carcinoma in diabetic patients Abdalla, Mona Mohamed Ibrahim World J Gastroenterol Review Hepatocellular carcinoma (HCC), the predominant type of liver cancer, is a major contributor to cancer-related fatalities across the globe. Diabetes has been identified as a significant risk factor for HCC, with recent research indicating that the hormone resistin could be involved in the onset and advancement of HCC in diabetic individuals. Resistin is a hormone that is known to be involved in inflammation and insulin resistance. Patients with HCC have been observed to exhibit increased resistin levels, which could be correlated with more severe disease stages and unfavourable prognoses. Nevertheless, the exact processes through which resistin influences the development and progression of HCC in diabetic patients remain unclear. This article aims to examine the existing literature on the possible use of resistin levels as a biomarker for HCC development and monitoring. Furthermore, it reviews the possible pathways of HCC initiation due to elevated resistin and offers new perspectives on comprehending the fundamental mechanisms of HCC in diabetic patients. Gaining a better understanding of these processes may yield valuable insights into HCC’s development and progression, as well as identify possible avenues for prevention and therapy. Baishideng Publishing Group Inc 2023-07-21 2023-07-21 /pmc/articles/PMC10401662/ /pubmed/37545641 http://dx.doi.org/10.3748/wjg.v29.i27.4271 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Review
Abdalla, Mona Mohamed Ibrahim
Serum resistin and the risk for hepatocellular carcinoma in diabetic patients
title Serum resistin and the risk for hepatocellular carcinoma in diabetic patients
title_full Serum resistin and the risk for hepatocellular carcinoma in diabetic patients
title_fullStr Serum resistin and the risk for hepatocellular carcinoma in diabetic patients
title_full_unstemmed Serum resistin and the risk for hepatocellular carcinoma in diabetic patients
title_short Serum resistin and the risk for hepatocellular carcinoma in diabetic patients
title_sort serum resistin and the risk for hepatocellular carcinoma in diabetic patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401662/
https://www.ncbi.nlm.nih.gov/pubmed/37545641
http://dx.doi.org/10.3748/wjg.v29.i27.4271
work_keys_str_mv AT abdallamonamohamedibrahim serumresistinandtheriskforhepatocellularcarcinomaindiabeticpatients